Next Article in Journal
Erratum: Debons et al. Magnetic Field Alignment, a Perspective in the Engineering of Collagen-Silica Composite Biomaterials. Biomolecules 2021, 11, 749
Next Article in Special Issue
Retrospective Analysis of INRG Clinical and Genomic Factors for 605 Neuroblastomas in Japan: A Report from the Japan Children’s Cancer Group Neuroblastoma Committee (JCCG-JNBSG)
Previous Article in Journal
Chlorophyllides: Preparation, Purification, and Application
Previous Article in Special Issue
How Do Telomere Abnormalities Regulate the Biology of Neuroblastoma?
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Commentary

Why Is Aneuploidy Associated with Favorable Outcome in Neuroblastoma?

by
Gian Paolo Tonini
Laboratory of Target Discovery and Biology of Neuroblastoma, Pediatric Research Institute, Città della Speranza, Corso Stati Uniti 4, 35127 Padova, Italy
Biomolecules 2021, 11(8), 1116; https://doi.org/10.3390/biom11081116
Submission received: 24 May 2021 / Revised: 23 July 2021 / Accepted: 26 July 2021 / Published: 29 July 2021
(This article belongs to the Special Issue Molecular and Biological Enigma of Neuroblastoma: How to Solve It?)

Abstract

:
Neuroblastoma is a pediatric cancer, onset with localized as well as metastatic disease. Localized tumors usually show a high content of aneuploid cells. It is suggested that aneuploid cells with numerical copy number variation (CNV) are generated by chromosome instability (CIN). Patients with a localized tumor respond well to the therapy and show a good outcome. On the contrary, patients with a metastatic tumor have worse outcomes and the cells with structural CNV show high levels of CIN. It is proposed that a favorable outcome in patients with localized disease is associated to the grade of CIN.

Neuroblastoma is a pediatric cancer showing great biological and clinical heterogeneity. The prognosis of neuroblastoma patients ranges from favorable to severe outcomes. Moreover, in about 70% of patients younger than one year of age, the tumor may undergo spontaneous or drug-induced regression [1,2]. This peculiar behavior of the neuroblastoma has not yet been solved.
The advent of new technologies such as an array comparative genomic hybridization (aCGH) [3], a genome wide association study (GWAS) [4], and whole-exome sequencing (WES) [5], have allowed us to clarify some aspects of different outcome in neuroblastoma patients [6].
In a normal situation, each cell has two copies of chromosomes and they are designated diploid cells. Localized tumors of patients under one year of age are usually characterized by aneuploidy, a numeric whole extra-chromosome copy number with or without structural abnormalities [1]. Aneuploidy is defined as the presence of an unbalanced number of chromosomes or large portions of chromosomes in a cell (Figure 1) [7].
How is generating the whole extra-chromosome numbers is not yet fully understood. It is generally accepted that they are produced by the malfunction of mitosis apparatus; for example, the failure of spindle bodies, resulting in an unequal chromosome number distribution in the daughter cells.
There are very few data about the activity of extra-copy chromosomes in neuroblastoma cells, but there are several indirect pieces of evidence that extra-chromosomes partially contribute to the tumor aggressiveness [8]. For instance, cells of localized tumors are not able to grow in vitro and in animals. As a consequence, it is plausible that aneuploid neuroblastoma cells have low aggressiveness, and the extra-chromosomes give a partial contribution to the tumor aggressiveness. Tumor cells of patients in stage 1 or 2 or 4S [9] are characterized by high aneuploidy, indicating that aneuploidy status is associated to tumors in patients with a good prognosis. On the contrary, neuroblastoma cells of stage 4 have gross structural chromosome damages including chromosome deletion, chromosome gain, and chromosome rearrangement, and they are very aggressive [9]. These structural chromosome variations were prevalent observed in the advanced clinical stage of patients with severe diagnosis. We have shown that neuroblastoma cells of metastatic stage 4 in patients older than 18 months have a higher percentage of structural chromosome copy number variations. It is possible that structural chromosome aberrations damage several genes.
The aneuploidy is characterized by chromosome instability (CIN). CIN is a complex phenomenon that mainly includes the chromosome mis-segregation [10,11,12,13,14]. It is possible that the aggressiveness of neuroblastoma cells depends on the degree of CIN.
It is difficult to define the degree of CIN, but many genes are involved in CIN: genes regulating mitosis and DNA repair genes have been reported with different methods for the assessment of chromosomal changes in solid cancer. The methods include different techniques to explore the CIN: interphase-FISH, flow cytometry, SNParray, Micronuclei counting, CGH array, digital PCR, and karyotyping. Carter et al. [15] have found a CIN gene signature for many cancers including neuroblastoma [16]. In view of the foregoing, the evaluation of degree of CIN appears very complex and many parameters have to be considered. All of the above information suggests the following assumption. The aggressiveness of the tumor depends mainly on the degree of CIN that generates aneuploidy and the grade of aneuploidy is associated with favorable outcomes in neuroblastoma.
This aspect should be taken into consideration when we include CIN-related drugs in the neuroblastoma therapy. [5].

Funding

Fondazione Italiana per La Lotta al Neuroblastoma.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Luksch, R.; Castellani, M.R.; Collini, P.; De Bernardi, B.; Conte, M.; Gambini, C.; Gandola, L.; Garaventa, A.; Biasoni, D.; Podda, M.; et al. Neuroblastoma (Peripheral neuroblastic tumours). Crit. Rev. Oncol. Hematol. 2016, 107, 163–181. [Google Scholar] [CrossRef] [PubMed]
  2. Matthay, K.K.; Maris, J.M.; Schleiermacher, G.; Nakagawara, A.; Mackall, C.L.; Diller, L.; Weiss, W.A. Neuroblastoma. Nat. Rev. Dis. Primers 2016, 2, 16078. [Google Scholar] [CrossRef] [PubMed]
  3. Defferrari, R.; Mazzocco, K.; Ambros, I.M.; Ambros, P.F.; Bedwell, C.; Beiske, K.; Bénard, J.; Berbegall, A.P.; Bown, N.; Combaret, V.; et al. Influence of chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification. Br. J. Cancer 2015, 112, 290–295. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Capasso, M.; Diskin, S.J.; Totaro, F.; Longo, L.; De Mariano, M.; Russo, R.; Cimmino, F.; Hakonarson, H.; Tonini, G.P.; Devoto, M.; et al. Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility. Carcinogenesis 2013, 34, 605–611. [Google Scholar] [CrossRef] [Green Version]
  5. Esposito, M.R.; Aveic, S.; Seydel, A.; Tonini, G.P. Neuroblastoma treatment in the post-genomic era. J. Biomed. Sci. 2017, 24, 14. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Zanon, C.; Tonini, G.P. Transcription instability in high-risk neuroblastoma is associated with a global perturbation of chroma-tin domains. Mol. Oncol. 2017, 11, 1646–1658. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Chi, Y.-H.; Jeang, K.-T. Aneuploidy and cancer. J. Cell. Biochem. 2007, 102, 531–538. [Google Scholar] [CrossRef]
  8. Coco, S.; Theissen, J.; Scaruffi, P.; Stigliani, S.; Moretti, S.; Oberthuer, A.; Valdora, F.; Fischer, M.; Gallo, F.; Hero, B.; et al. Age-dependent accumulation of genomic aberrations and deregulation of cell cycle and telomerase genes in metastatic neuroblastoma. Int. J. Cancer 2012, 131, 1591–1600. [Google Scholar] [CrossRef] [PubMed]
  9. De Bernardi, B.; Di Cataldo, A.; Garaventa, A.; Massirio, P.; Viscardi, E.; Podda, M.G.; Castellano, A.; D’Angelo, P.; Tirtei, E.; Melchionda, F.; et al. Stage 4 s neuroblastoma: Features, management and outcome of 268 cases from the Italian Neuroblastoma Registry. Ital. J. Pediatr. 2019, 45, 8. [Google Scholar] [CrossRef] [PubMed]
  10. Bakhoum, S.F.; Kabeche, L.; Compton, D.A.; Powell, S.N.; Bastians, H. Mitotic DNA damage response: At the crossroads of structural and numerical cancer chromosome instabilities. Trends Cancer 2017, 3, 225–234. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  11. Bakhoum, S.F.; Compton, D. Chromosomal instability and cancer: A complex relationship with therapeutic potential. J. Clin. Investig. 2012, 122, 1138–1143. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Thompson, S.L.; Bakhoum, S.F.; Compton, D.A. Mechanisms of chromosomal instability. Curr. Biol. 2010, 20, R285–R295. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Thompson, S.L.; Compton, D.A. Chromosomes and cancer cells. Chromosom. Res. 2010, 19, 433–444. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Geigl, J.B.; Obenauf, A.C.; Schwarzbraun, T.; Speicher, M.R. Defining ‘chromosomal instability’. Trends Genet. 2008, 24, 64–69. [Google Scholar] [CrossRef] [PubMed]
  15. Carter, S.L.; Eklund, A.C.; Kohane, I.S.; Harris, L.N.; Szallasi, Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat. Genet. 2006, 38, 1043–1048. [Google Scholar] [CrossRef] [PubMed]
  16. Fusco, P.; Esposito, M.R.; Tonini, G.P. Chromosome instability inneuroblastoma. Oncol. Lett. 2018, 16, 6887–6894. [Google Scholar] [PubMed]
Figure 1. In the figure is a schematic illustrated the hypothesis of the formation of aneuploidy neuroblastoma cells. It is widely accepted that neuroblastoma origins from Neural Crest Cells (NCC). NCC (green circle) are a group of neural crest cells in which the CIN is very low and present in few cells (pink circle). After birth of the baby, the number of cells (blue circle) with chromosome extra-copies increases. The cells have a high numerical Copy Number Variation (nCNV) and form aneuploid cells of tumors of favorable disease. After the first year of life the tumor cells accumulate several structural Copy Number Variations (sCNV), producing aggressive neuroblastoma cells (red circle).
Figure 1. In the figure is a schematic illustrated the hypothesis of the formation of aneuploidy neuroblastoma cells. It is widely accepted that neuroblastoma origins from Neural Crest Cells (NCC). NCC (green circle) are a group of neural crest cells in which the CIN is very low and present in few cells (pink circle). After birth of the baby, the number of cells (blue circle) with chromosome extra-copies increases. The cells have a high numerical Copy Number Variation (nCNV) and form aneuploid cells of tumors of favorable disease. After the first year of life the tumor cells accumulate several structural Copy Number Variations (sCNV), producing aggressive neuroblastoma cells (red circle).
Biomolecules 11 01116 g001
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Tonini, G.P. Why Is Aneuploidy Associated with Favorable Outcome in Neuroblastoma? Biomolecules 2021, 11, 1116. https://doi.org/10.3390/biom11081116

AMA Style

Tonini GP. Why Is Aneuploidy Associated with Favorable Outcome in Neuroblastoma? Biomolecules. 2021; 11(8):1116. https://doi.org/10.3390/biom11081116

Chicago/Turabian Style

Tonini, Gian Paolo. 2021. "Why Is Aneuploidy Associated with Favorable Outcome in Neuroblastoma?" Biomolecules 11, no. 8: 1116. https://doi.org/10.3390/biom11081116

APA Style

Tonini, G. P. (2021). Why Is Aneuploidy Associated with Favorable Outcome in Neuroblastoma? Biomolecules, 11(8), 1116. https://doi.org/10.3390/biom11081116

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop